Celcuity Inc.
CELC- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- SEC CIK
- 0001603454
No open-market purchases or sales by Celcuity Inc. insiders were filed in the last 90 days; 275 institutions reported holding it in 13F filings for Q2 2026, worth $5.95B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:54 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 25, 2026 | Mar 31, 2025 | Mar 27, 2024 | Mar 23, 2023 | Mar 23, 2022 |
| Operating expenses | $172.2M | $113.3M | $66.2M | $39.4M | $28.4M |
| Research and development | $145.0M | $104.2M | $60.6M | $35.3M | $25.8M |
| Selling, general and administrative | $27.2M | $9.06M | $5.64M | $4.10M | $2.60M |
| Operating income | -$172.2M | -$113.3M | -$66.2M | -$39.4M | -$28.4M |
| Interest expense | $14.4M | – | $5.33M | $2.11M | $1.26M |
| Net income | -$177.0M | -$111.8M | -$63.8M | -$40.4M | -$29.6M |
| EPS, basic | $-3.79 | $-2.83 | $-2.69 | $-2.64 | – |
| EPS, diluted | $-3.79 | $-2.83 | $-2.69 | – | – |
| Weighted shares, basic | 46.8M | 39.4M | 23.7M | 15.4M | – |
| Weighted shares, diluted | 46.8M | 39.4M | 23.7M | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 25, 2026 | Mar 31, 2025 | Mar 27, 2024 | Mar 23, 2023 | Mar 23, 2022 |
| Cash and equivalents | $165.7M | $22.5M | $30.7M | $24.6M | $84.3M |
| Short-term investments | $275.8M | $212.6M | $149.9M | $144.0M | – |
| Total current assets | $465.7M | $244.6M | $190.6M | $175.2M | $85.4M |
| Property, plant and equipment | $499.0K | $336.5K | $228.8K | $260.3K | $312.4K |
| Total assets | $466.6M | $245.1M | $191.2M | $175.7M | $85.9M |
| Accounts payable | $6.41M | $9.37M | $5.08M | $2.63M | $1.51M |
| Total current liabilities | $44.2M | $31.7M | $14.2M | $6.88M | $2.51M |
| Long-term debt | $137.5M | $105.1M | $37.6M | $35.8M | $16.0M |
| Total liabilities | $366.0M | $129.5M | $51.5M | $41.9M | $17.2M |
| Shareholders' equity | $100.6M | $115.6M | $139.8M | $133.8M | $68.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 25, 2026 | Mar 31, 2025 | Mar 27, 2024 | Mar 23, 2023 | Mar 23, 2022 |
| Operating cash flow | -$153.3M | -$83.5M | -$53.8M | -$36.0M | -$20.3M |
| Capital expenditures | $249.0K | $249.9K | $97.6K | $158.8K | $81.9K |
| Free cash flow | -$153.5M | -$83.7M | -$53.9M | -$36.2M | -$20.4M |
| Stock-based compensation | $21.4M | $6.99M | $4.90M | $4.64M | $2.61M |
| Investing cash flow | -$64.1M | -$63.1M | -$5.01M | -$144.0M | -$81.4K |
| Financing cash flow | $360.6M | $138.4M | $64.9M | $120.3M | $93.0M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 29, 2026 | 49.1M | +6.2% | SEC |
| Aug 5, 2026 | 48.9M | +15.3% | SEC |
| May 7, 2026 | 48.8M | +28.8% | SEC |
| Mar 17, 2026 | 48.3M | +27.7% | SEC |
| Nov 6, 2025 | 46.3M | +24.6% | SEC |
| Aug 7, 2025 | 42.4M | +14.6% | SEC |
| May 7, 2025 | 37.9M | +21.2% | SEC |
| Mar 24, 2025 | 37.8M | +24.3% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.